Comparable Results Between 8 and 12 Gray <scp>TBI</scp> in Combination With Fludarabine and Post‐Transplant Cyclophosphamide in <scp>MRD</scp>‐Negative but Not in <scp>MRD</scp>‐Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Com
Our study demonstrates that 8 Gy TBI in comparison to 12 Gy TBI results in low NRM but a high relapse rate with similar OS, LFS, and GRFS. In MRD+ high-risk ALL patients, allogeneic SCT with 12 Gy TBI leads to improved OS, LFS, GRFS, and a low relapse rate. Prospective studies comparing the different treatment regimens with larger MRD patient cohorts are needed to confirm this data.
Authors
- Ina Rudolph
- Kristin Rathje
- Gaby Zeck
- Radwan Massoud (ORCID: https://orcid.org/0000-0001-9275-3840)
- Johanna Richter (ORCID: https://orcid.org/0000-0002-2043-0003)
- Normann Steiner
- Nico Gagelmann (ORCID: https://orcid.org/0000-0002-0891-1744)
- Dietlinde Janson
- Silke Heidenreich
- Christine Wolschke
- Christian Niederwieser (ORCID: https://orcid.org/0000-0002-0114-1011)
- Francis Ayuk (ORCID: https://orcid.org/0000-0001-6297-1847)
- Evgeny Klyuchnikov (ORCID: https://orcid.org/0000-0001-9407-1413)
- Tetiana Perekhrestenko (ORCID: https://orcid.org/0009-0008-9041-435X)
- Mathias Schäfersküpper
- Iryna Lastovytska
- Nicolaus Kröger
Institutions
- Innsbruck Medical University (AT)
- Universität Hamburg (DE)
- Universität Innsbruck (AT)
- Shupyk National Healthcare University of Ukraine (UA)
- University Medical Center Hamburg-Eppendorf (DE)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1111/ejh.14305
- Citations
- 1
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.54